Khan K. Pioglitazone for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes: A Meta-Analysis. IJMBS [Internet]. 2025 Feb. 27 [cited 2026 Apr. 27];9(1):259-64. Available from: https://www.ijmbs.info/index.php/ijmbs/article/view/3091